Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Apr 30

PMID 33924793

Citations 32

Authors

Yongzhen Liu

Stephanie Maya

Alexander Ploss

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B virus (HBV) infection affects more than 250 million people worldwide, which greatly increases the risk for terminal liver diseases, such as liver cirrhosis and hepatocellular carcinoma (HCC). Even though current approved antiviral therapies, including pegylated type I interferon (IFN) and nucleos(t)ide analogs, can effectively suppress viremia, HBV infection is rarely cured. Since HBV exhibits a narrow species tropism and robustly infects only humans and higher primates, progress in HBV research and preclinical testing of antiviral drugs has been hampered by the scarcity of suitable animal models. Fortunately, a series of surrogate animal models have been developed for the study of HBV. An increased understanding of the barriers towards interspecies transmission has aided in the development of human chimeric mice and has greatly paved the way for HBV research in vivo, and for evaluating potential therapies of chronic hepatitis B. In this review, we summarize the currently available animal models for research of HBV and HBV-related hepadnaviruses, and we discuss challenges and future directions for improvement.

Citing Articles

Flavonoids of Andrographis paniculata regulate hepatitis B virus replication and hepatocellular carcinoma progression: evidence from computational and experimental studies.

Patil V, Harish D, Charla R, Bhandare V, Gujarathi S, Beerwala F BMC Complement Med Ther. 2025; 25(1):95.

PMID: 40057777 PMC: 11889761. DOI: 10.1186/s12906-025-04807-z.

Probiotics and their metabolite spermidine enhance IFN-γCD4 T cell immunity to inhibit hepatitis B virus.

Wang T, Fan Y, Tan S, Wang Z, Li M, Guo X Cell Rep Med. 2024; 5(11):101822.

PMID: 39536754 PMC: 11604485. DOI: 10.1016/j.xcrm.2024.101822.

Structural basis for hepatitis B virus restriction by a viral receptor homologue.

Shionoya K, Park J, Ekimoto T, Takeuchi J, Mifune J, Morita T Nat Commun. 2024; 15(1):9241.

PMID: 39455604 PMC: 11511851. DOI: 10.1038/s41467-024-53533-6.

The feasibility of establishing a hamster model for HBV infection: evidence.

Zhang H, Liu Y, Liu C, Wang Z, Guo H mBio. 2024; 15(11):e0261524.

PMID: 39329526 PMC: 11559161. DOI: 10.1128/mbio.02615-24.

Progress of Infection and Replication Systems of Hepatitis B Virus.

Zhang T, Yang J, Gao H, Wu Y, Zhao X, Zhao H ACS Pharmacol Transl Sci. 2024; 7(6):1711-1721.

PMID: 38898948 PMC: 11184603. DOI: 10.1021/acsptsci.4c00147.

References

Nakabori T, Hikita H, Murai K, Nozaki Y, Kai Y, Makino Y . Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci Rep. 2016; 6:27782. PMC: 4899802. DOI: 10.1038/srep27782. View

Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y . Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. PLoS One. 2015; 10(8):e0134539. PMC: 4543549. DOI: 10.1371/journal.pone.0134539. View

Sells M, Chen M, Acs G . Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987; 84(4):1005-9. PMC: 304350. DOI: 10.1073/pnas.84.4.1005. View

Walter E, Keist R, Niederost B, Pult I, Blum H . Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology. 1996; 24(1):1-5. DOI: 10.1002/hep.510240101. View

Bartenschlager R, Schaller H . A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 1990; 9(10):3389-96. PMC: 552077. DOI: 10.1002/j.1460-2075.1990.tb07540.x. View

Cui X, Guo J, Hu J . Hepatitis B Virus Covalently Closed Circular DNA Formation in Immortalized Mouse Hepatocytes Associated with Nucleocapsid Destabilization. J Virol. 2015; 89(17):9021-8. PMC: 4524059. DOI: 10.1128/JVI.01261-15. View

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

Lanford R, Chavez D, Brasky K, Burns 3rd R, Rico-Hesse R . Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A. 1998; 95(10):5757-61. PMC: 20452. DOI: 10.1073/pnas.95.10.5757. View

Lang J, Neumann-Haefelin C, Thimme R . Immunological cure of HBV infection. Hepatol Int. 2019; 13(2):113-124. DOI: 10.1007/s12072-018-9912-8. View

10.

Wang Y, Chen K, Wu Z, Liu Y, Liu S, Zou Z . Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice. Int J Infect Dis. 2014; 29:31-6. PMC: 4397646. DOI: 10.1016/j.ijid.2014.07.015. View

11.

Yan R, Su J, Huang D, Gan Y, Yang C, Huang G . Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J Cancer Res Clin Oncol. 1996; 122(5):283-8. DOI: 10.1007/BF01261404. View

12.

Menne S, Tumas D, Liu K, Thampi L, Aldeghaither D, Baldwin B . Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015; 62(6):1237-45. PMC: 4439359. DOI: 10.1016/j.jhep.2014.12.026. View

13.

Sohn H, Min B, Song J, Seong M, Lee S, Jang E . Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014; 14:439. PMC: 4148928. DOI: 10.1186/1471-2334-14-439. View

14.

Kock J, Nassal M, MacNelly S, Baumert T, Blum H, von Weizsacker F . Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol. 2001; 75(11):5084-9. PMC: 114913. DOI: 10.1128/JVI.75.11.5084-5089.2001. View

15.

Heckel J, Sandgren E, Degen J, Palmiter R, Brinster R . Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell. 1990; 62(3):447-56. DOI: 10.1016/0092-8674(90)90010-c. View

16.

Sandgren E, Palmiter R, Heckel J, Daugherty C, Brinster R, Degen J . Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell. 1991; 66(2):245-56. DOI: 10.1016/0092-8674(91)90615-6. View

17.

Winer B, Ding Q, Gaska J, Ploss A . In vivo models of hepatitis B and C virus infection. FEBS Lett. 2016; 590(13):1987-99. PMC: 4945464. DOI: 10.1002/1873-3468.12157. View

18.

Drexler J, Geipel A, Konig A, Corman V, van Riel D, Leijten L . Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci U S A. 2013; 110(40):16151-6. PMC: 3791787. DOI: 10.1073/pnas.1308049110. View

19.

Ange-van Heugten K, Burns R, Verstegen M, Jansen W, Ferket P, van Heugten E . Evaluation of diabetes determinants in woolly monkeys (Lagothrix lagotricha). J Anim Physiol Anim Nutr (Berl). 2007; 91(11-12):481-91. DOI: 10.1111/j.1439-0396.2007.00679.x. View

20.

Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H, Yokomichi H . Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice. PLoS One. 2015; 10(11):e0142145. PMC: 4633119. DOI: 10.1371/journal.pone.0142145. View